Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, thank you for standing by. At this time, all participants are in a listen-only mode. After the speakers’ presentation ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

Israeli scientists have identified a promising new factor in the pathology of Parkinson’s disease that could pave the way for ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...

Researchers have identified a protein, TMEM16F, that appears to aid the spread of Parkinson’s pathology in the brain.

to develop exercise equipment for Parkinson’s Disease patients in the area. One result of Hunter’s efforts includes a machine ...

Net income: The net income attributable to Serina for the three months ended September 30, 2024 was $1.4 million, or $0.16 per share (basic) and $0.13 per share (diluted) compared to net income of ...

Alzheimer’s Disease · Amyotrophic Lateral Sclerosis (ALS) · Autism · ADHD · Schizophrenia · Stroke · Brain Tumors · Multiple Sclerosis · Parkinson’s Disease · Epilepsy and Seizures · Dyslexia · ...